Probiotics
Live microorganisms that may benefit health when taken at adequate doses. Evidence is strongly STRAIN-specific — 'probiotics' as a generic category does little. Best-evidenced uses are preventing antibiotic-associated diarrhea, treating IBS, and shortening acute infectious diarrhea in children.
Quick decision guide
May help most
Anyone starting a course of antibiotics — to reduce the risk of antibiotic-associated diarrhea and C. difficile infection.
Common dosing range
5-40 billion CFU/day of a studied strain. Strain identity matters more than total CFU count.
When to expect effects
Days for diarrhea prevention; 4-12 weeks for IBS symptom improvement.
Watch out for
Avoid in critically ill, immunocompromised, or central-venous-catheter patients — rare reports of bacteremia / fungemia. Generic 'gut health' marketing is mostly unsupported.
Evidence snapshot
What is it
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. They are most commonly bacteria from the Lactobacillus and Bifidobacterium genera, but also include yeast such as Saccharomyces boulardii.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Antibiotic-associated diarrhea prevention Strong Evidence | ~40-55% relative reduction in AAD risk; absolute risk reduction depends on baseline (NNT ~10-15) | Anyone on broad-spectrum antibiotics; pediatric and adult populations both supported; higher absolute benefit when baseline AAD risk is high (hospitalized, elderly, clindamycin/cephalosporins/fluoroquinolones) | Begin within 48 hours of starting antibiotics; effect over the antibiotic course |
Acute infectious diarrhea (children) Strong Evidence | ~25 hour reduction in diarrhea duration; ~60% reduction in diarrhea lasting >=4 days | Children with acute viral or bacterial gastroenteritis, started in the first 48 hours of symptoms | Within the diarrhea episode (24-72 hours) |
Pouchitis maintenance (VSL#3 / Visbiome) Strong Evidence | ~85% remission maintenance vs ~6% placebo at 12 months (in chronic relapsing pouchitis) | Patients with chronic relapsing pouchitis after total proctocolectomy with ileoanal anastomosis | Weeks (after antibiotic-induced remission) |
C. difficile-associated diarrhea prevention Good Evidence | ~60% relative reduction in CDI in higher-risk groups (baseline risk >5%) | Hospitalized patients on broad-spectrum antibiotics with baseline CDI risk >5%; elderly adults, prior CDI episode, immunocompromise (with caution) | During and 1-2 weeks after the antibiotic course |
Irritable bowel syndrome (IBS) Good Evidence | Modest reduction in global IBS symptoms; abdominal pain and bloating respond more reliably than altered bowel habits | Adults with IBS-D or mixed IBS willing to trial a multi-strain product for 8-12 weeks | 4-12 weeks; stop if no improvement at 12 weeks |
Atopic dermatitis (eczema) prevention in infants Limited Evidence | Mixed; some strain combinations show OR ~0.5 for incident atopic dermatitis, others show no effect | High-risk infants (strong family history of atopic disease) with obstetrician input | Months (pre- and post-natal use) |
Bacterial vaginosis / vaginal health Limited Evidence | Possible improvement in cure rates and reduction in recurrence when used alongside metronidazole; not a standalone treatment | Women with recurrent BV considering adjunctive Lactobacillus alongside standard antibiotic therapy | Weeks during and after antibiotic course |
Antibiotic-associated diarrhea prevention
- Effect
- ~40-55% relative reduction in AAD risk; absolute risk reduction depends on baseline (NNT ~10-15)
- Best fit
- Anyone on broad-spectrum antibiotics; pediatric and adult populations both supported; higher absolute benefit when baseline AAD risk is high (hospitalized, elderly, clindamycin/cephalosporins/fluoroquinolones)
- Time
- Begin within 48 hours of starting antibiotics; effect over the antibiotic course
Acute infectious diarrhea (children)
- Effect
- ~25 hour reduction in diarrhea duration; ~60% reduction in diarrhea lasting >=4 days
- Best fit
- Children with acute viral or bacterial gastroenteritis, started in the first 48 hours of symptoms
- Time
- Within the diarrhea episode (24-72 hours)
Pouchitis maintenance (VSL#3 / Visbiome)
- Effect
- ~85% remission maintenance vs ~6% placebo at 12 months (in chronic relapsing pouchitis)
- Best fit
- Patients with chronic relapsing pouchitis after total proctocolectomy with ileoanal anastomosis
- Time
- Weeks (after antibiotic-induced remission)
C. difficile-associated diarrhea prevention
- Effect
- ~60% relative reduction in CDI in higher-risk groups (baseline risk >5%)
- Best fit
- Hospitalized patients on broad-spectrum antibiotics with baseline CDI risk >5%; elderly adults, prior CDI episode, immunocompromise (with caution)
- Time
- During and 1-2 weeks after the antibiotic course
Irritable bowel syndrome (IBS)
- Effect
- Modest reduction in global IBS symptoms; abdominal pain and bloating respond more reliably than altered bowel habits
- Best fit
- Adults with IBS-D or mixed IBS willing to trial a multi-strain product for 8-12 weeks
- Time
- 4-12 weeks; stop if no improvement at 12 weeks
Atopic dermatitis (eczema) prevention in infants
- Effect
- Mixed; some strain combinations show OR ~0.5 for incident atopic dermatitis, others show no effect
- Best fit
- High-risk infants (strong family history of atopic disease) with obstetrician input
- Time
- Months (pre- and post-natal use)
Bacterial vaginosis / vaginal health
- Effect
- Possible improvement in cure rates and reduction in recurrence when used alongside metronidazole; not a standalone treatment
- Best fit
- Women with recurrent BV considering adjunctive Lactobacillus alongside standard antibiotic therapy
- Time
- Weeks during and after antibiotic course
Evidence for 7 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Antibiotic-associated diarrhea prevention
Supplement benefitThe most consistently replicated probiotic benefit. The 2019 Cochrane review of 33 pediatric RCTs found a 55% reduction in AAD risk (RR 0.45). Hempel's JAMA meta-analysis in adults (63 RCTs, ~12,000 people) found a 42% reduction (RR 0.58). Lactobacillus rhamnosus GG and Saccharomyces boulardii are the best-evidenced strains. Start the probiotic within 48 hours of the antibiotic and continue throughout the course plus a few days after.
Bottom line: If you're prescribed antibiotics, take 5-10 billion CFU/day of L. rhamnosus GG or S. boulardii starting the same day. Separate doses by 2 hours from the antibiotic.
Acute infectious diarrhea (children)
Supplement benefitThe 2010 Cochrane review (35 RCTs, ~4,500 patients) found probiotics shortened acute diarrhea duration by ~25 hours and reduced risk of diarrhea lasting >=4 days by ~60%. L. rhamnosus GG and S. boulardii at 10 billion CFU/day for 5 days are the best-supported regimens. The European Society for Paediatric Gastroenterology (ESPGHAN) recommends probiotics for acute gastroenteritis alongside oral rehydration.
Bottom line: Add LGG or S. boulardii to oral rehydration in children with acute diarrhea — likely shortens the episode by a day. Doesn't replace fluid replacement.
Pouchitis maintenance (VSL#3 / Visbiome)
Disease adjunctHigh-dose 8-strain VSL#3 (now sold as Visbiome in the U.S.) is the only probiotic with strong evidence for inflammatory bowel disease. Multiple RCTs in patients with chronic relapsing pouchitis after ileoanal anastomosis show ~85% maintenance of remission vs ~6% on placebo at 12 months. The very specific strain blend, manufacturing process, and dose (450 billion to 1.8 trillion CFU/day) make this one of the few cases where a specific branded product matters.
Bottom line: Use under a gastroenterologist's care for pouchitis. Don't switch brands — the specific VSL#3/Visbiome formulation is what was tested.
C. difficile-associated diarrhea prevention
Supplement benefitThe 2017 Cochrane review of 31 RCTs (~8,700 patients) found probiotics moderately reduced CDI risk during antibiotic therapy (RR 0.40, 95% CI 0.30-0.52). Benefit was greatest when baseline CDI risk exceeded 5%, which is typical of hospitalized older adults on broad-spectrum antibiotics. Major guideline bodies have not fully endorsed routine use because the benefit-to-risk ratio in lower-risk outpatient settings is unclear.
Bottom line: Useful adjunct in hospital antibiotic exposures, especially in high-CDI-risk patients. Discuss with the prescriber if there's a central line or recent immunosuppression.
Irritable bowel syndrome (IBS)
Supplement benefitFord et al.'s 2018 meta-analysis (53 RCTs, ~5,500 patients) found probiotics modestly improved overall IBS symptoms vs placebo (RR of no improvement 0.79). Multi-strain combinations including Lactobacillus and Bifidobacterium were most consistently effective. Individual strains (Bifidobacterium infantis 35624 / Align) have small RCT evidence. Heterogeneity is high and the AGA conditionally recommends against probiotics for IBS in adults outside clinical trials — disagreement with the meta-analysis reflects honestly mixed signal.
Bottom line: A reasonable 8-12 week trial of a multi-strain Lactobacillus + Bifidobacterium product is worth trying for IBS — stop if you don't notice clear improvement.
Evidence is mixed
The 2018 ACG/AJG meta-analysis (Ford) showed benefit; the 2020 American Gastroenterological Association (AGA) clinical practice guideline conditionally recommends AGAINST probiotics in adult IBS outside trial settings. Both can be right — the average effect is real but small, and strain/quality varies wildly across consumer products.
Atopic dermatitis (eczema) prevention in infants
Supplement benefitNetwork meta-analysis suggests mixed Lactobacillus paracasei + L. fermentum given to mothers during pregnancy and to infants in the first months may reduce atopic dermatitis incidence. Effect sizes vary widely across strains; single-strain products have weaker evidence. National guidelines (NICE, AAP) do not currently recommend routine probiotic supplementation for eczema prevention.
Bottom line: Modest, strain-specific signal for prevention in high-risk infants. Talk to your pediatrician — not a routine recommendation.
Bacterial vaginosis / vaginal health
Supplement benefitSome evidence that adjunctive oral or vaginal Lactobacillus (especially L. crispatus, L. rhamnosus GR-1 + L. reuteri RC-14) improves bacterial vaginosis cure rates when added to metronidazole. The 2009 Cochrane review and subsequent reviews call evidence insufficient for routine recommendation as monotherapy. Trials are small, strains and formats (oral vs vaginal capsules) vary, and recurrence rates are high regardless.
Bottom line: Adjunctive role at best — discuss with your gynecologist if BV keeps recurring. Don't skip standard antibiotic therapy.
How it works
How to take it
What to track
Bottom line: Match the strain to the indication. 5-40 billion CFU/day of a named strain with food. Generic 'probiotic blend' products have generic (i.e. weak) evidence.
6 commercial forms
Compare the main delivery options and what they’re best suited for.
Lactobacillus rhamnosus GG (LGG)
Best evidenceThe single most-studied probiotic strain. Strong evidence for AAD prevention (adults + children), acute infectious diarrhea (children), and prevention of atopic eczema (specific contexts). Sold OTC by multiple brands (Culturelle is the U.S. licensed product).
Survives stomach acid well; 5-10 billion CFU/day is the standard dose.
Saccharomyces boulardii CNCM I-745
Antibiotic-resistantA yeast (not bacteria), so it's naturally resistant to antibiotics — useful for AAD and C. difficile prevention. Strong evidence for AAD, CDI, and acute infectious diarrhea. Sold as Florastor in the U.S.
Yeast cells; not affected by concurrent antibiotics.
Multi-strain Lactobacillus + Bifidobacterium
IBS first-lineCombinations including L. acidophilus, L. plantarum, B. lactis, B. infantis at 10-50 billion CFU/day. Best evidence is for IBS symptom improvement. Brands vary widely in strain identity and quality — pick one that names strains and is third-party verified.
Quality varies widely; insist on strain-level labeling.
VSL#3 / Visbiome (8-strain high-dose)
Pouchitis-specificPatented blend of 4 Lactobacillus + 3 Bifidobacterium + 1 Streptococcus thermophilus at 450 billion to 1.8 trillion CFU per sachet. The only probiotic with replicated RCT evidence for chronic pouchitis maintenance. Branded as Visbiome in the U.S. (formula switch from original VSL#3 occurred in 2016 — most trials used the original; Visbiome is the closest formulation match).
Refrigerated; very high CFU specifically designed to deliver intact organisms to the colon.
Bifidobacterium infantis 35624 (Align)
Single-strain IBSOne of the few single-strain probiotics with RCT evidence in IBS. Modest effect on abdominal pain and bloating. Sold as Align.
1 billion CFU/day is the studied dose.
Fermented foods (yogurt, kefir, sauerkraut, kimchi)
Food-basedContain live cultures but at variable, generally lower CFU counts than supplements. Strains rarely identified to strain-code level. Reasonable for general gut-microbiome support; not a substitute for targeted strain supplementation when treating a specific condition.
CFU varies wildly; some yogurts have <1 million CFU per serving.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Rare reports of bacteremia or fungemia (Lactobacillus rhamnosus, Saccharomyces boulardii) in critically ill, immunocompromised, or central-venous-catheter patients. Mortality in case reports is significant — avoid probiotics in these populations unless guided by an infectious-disease specialist.
Probiotic-induced D-lactic acidosis has been reported in patients with short bowel syndrome — features brain fog, ataxia, slurred speech with metabolic acidosis.
Premature infants in the NICU should only receive probiotics under specialist supervision — case reports of fatal infections have prompted FDA warnings about specific products.
Who should avoid it
- Critically ill patients in ICU settings (especially with central venous catheters) — avoid Saccharomyces boulardii in particular.
- Severely immunocompromised patients: active leukemia, post-allogeneic transplant, advanced HIV with low CD4, severe neutropenia, active chemotherapy with prolonged neutropenia.
- Premature infants — outside of specifically researched NICU protocols.
- Patients with active short bowel syndrome — risk of D-lactic acidosis with selected Lactobacillus strains.
Pregnancy & breastfeeding
Lactobacillus and Bifidobacterium probiotics from food (yogurt, kefir) are generally considered safe during pregnancy. Supplement use has been studied in trials for atopic disease prevention without safety signals. Discuss high-dose or specific-indication probiotics with your obstetrician.
Bottom line: Safe for healthy adults and children. The real concern is critically ill, immunocompromised, or central-line patients — discuss with a clinician before use.
Interactions
Documented bloodstream infections traced to probiotic organisms (especially S. boulardii). Avoid probiotics in patients with indwelling central lines.
Theoretical risk of probiotic organism translocation in immunosuppressed states. Discuss with the prescribing transplant team or rheumatologist before use.
S. boulardii is a yeast; concurrent systemic antifungals can reduce or eliminate its probiotic effect and complicate interpretation if blood cultures grow yeast.
Antibiotics can kill some live probiotic organisms if taken at the same moment. Separate doses by 2 hours. (S. boulardii, a yeast, is naturally resistant to antibacterial agents.)
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance — a complement to the narrative section above.
Warnings (4)
+ immunosuppressants
highIn people whose immune systems are pharmacologically suppressed (for example by calcineurin inhibitors, mTOR inhibitors, corticosteroids, or mycophenolate), live probiotic organisms can occasionally cross the gut wall and enter the bloodstream, causing bacteremia, endocarditis, or sepsis. Case reports and a matched case-control study document Lactobacillus and Bifidobacterium bloodstream infections in transplant and oncology patients, with some strains naturally resistant to first-line antibiotics. The event is uncommon but serious.
+ chemotherapy
highChemotherapy can lower infection-fighting white blood cells and damage the gut lining, allowing live organisms from probiotic supplements to cross into the bloodstream and cause serious infection.
+ antifungals
moderateSystemic antifungals (such as fluconazole, itraconazole, amphotericin B, and the echinocandins) can kill yeast-based probiotics such as Saccharomyces boulardii, blunting their benefit. Bacterial probiotics like Lactobacillus and Bifidobacterium are generally unaffected, because their cell structure differs from fungi.
+ antibiotics
lowTaken at the same moment, an antibiotic can kill bacterial probiotic organisms before they reach the gut, lowering the probiotic's benefit. Spacing the doses apart fixes it.
Beneficial pairs (2)
+ prebiotics
synergyPrebiotics are non-digestible fibers (like inulin, FOS, and GOS) that some gut bacteria ferment for fuel. Pairing them with a probiotic creates what scientists call a 'synbiotic.' The pairing is plausible and generally well tolerated, but evidence that the combination clearly beats either ingredient on its own is mixed and depends on the condition and the specific strains used.
+ vitamin d
synergyVitamin D and probiotics act on overlapping pathways in the gut. Vitamin D supports vitamin D receptor (VDR) activity in the intestinal lining, which probiotics rely on for their anti-inflammatory and barrier-strengthening effects, while some probiotic strains appear to modestly raise circulating vitamin D. Randomized trials suggest combined supplementation can outperform either alone for some inflammatory and gut-barrier endpoints, though the evidence base is still limited.
Food sources
| Food | Amount | %DV |
|---|---|---|
| Yogurt with live active cultures | 1 cup (~1-10 billion CFU) | — |
| Kefir, plain | 1 cup (~5-15 billion CFU) | — |
| Sauerkraut, raw unpasteurized | ½ cup (variable CFU) | — |
| Kimchi, raw unpasteurized | ½ cup (variable CFU) | — |
| Tempeh | 3 oz (varies; some strains) | — |
| Miso paste | 1 Tbsp (live cultures if unpasteurized) | — |
| Kombucha | 8 oz (modest yeast + bacteria) | — |
| Aged cheeses (gouda, cheddar, mozzarella) | 1 oz (some live cultures) | — |
Yogurt with live active cultures
- Amount
- 1 cup (~1-10 billion CFU)
- %DV
- —
Kefir, plain
- Amount
- 1 cup (~5-15 billion CFU)
- %DV
- —
Sauerkraut, raw unpasteurized
- Amount
- ½ cup (variable CFU)
- %DV
- —
Kimchi, raw unpasteurized
- Amount
- ½ cup (variable CFU)
- %DV
- —
Tempeh
- Amount
- 3 oz (varies; some strains)
- %DV
- —
Miso paste
- Amount
- 1 Tbsp (live cultures if unpasteurized)
- %DV
- —
Kombucha
- Amount
- 8 oz (modest yeast + bacteria)
- %DV
- —
Aged cheeses (gouda, cheddar, mozzarella)
- Amount
- 1 oz (some live cultures)
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Are all probiotics the same?⌄
No. Probiotic effects are strain-specific. Lactobacillus rhamnosus GG, Saccharomyces boulardii, and Bifidobacterium infantis 35624 all have different uses. Match the strain to the intended use rather than choosing by CFU count or brand name.
Do I need refrigerated probiotics?⌄
Some strains require refrigeration to remain viable; others are shelf-stable. Check the label. Newer manufacturing methods have improved shelf stability of many strains.
Should I take probiotics with antibiotics?⌄
Yes, certain strains (especially Saccharomyces boulardii and Lactobacillus rhamnosus GG) reduce antibiotic-associated diarrhea risk. Separate the probiotic from the antibiotic by at least 2 hours. Continue for a week or two after finishing antibiotics.
Can probiotics colonize my gut permanently?⌄
Most probiotics do not permanently colonize the gut; they pass through. This is why consistent daily intake is needed for ongoing benefits. Long-term changes in microbiome composition usually require dietary and lifestyle changes.
Are probiotics safe for everyone?⌄
Generally yes, but immunocompromised individuals, those with central venous catheters, and critically ill patients should consult a clinician due to rare risks of serious infections.
References by claim
Safety
NIH Office of Dietary Supplements — Probiotics — Health Professional Fact Sheet (2024) link
Antibiotic-associated diarrhea prevention
C. difficile-associated diarrhea prevention
Goldenberg et al., 2017 (Cochrane) — Cochrane Database of Systematic Reviews (2017) link
Irritable bowel syndrome (IBS)
Ford et al., 2018 — American Journal of Gastroenterology (2018) link
Acute infectious diarrhea (children)
Allen et al., 2010 (Cochrane) — Cochrane Database of Systematic Reviews (2010) link
Pouchitis maintenance (VSL#3 / Visbiome)
Bacterial vaginosis / vaginal health
Senok et al., 2009 (Cochrane) — Cochrane Database of Systematic Reviews (2009) link
Atopic dermatitis (eczema) prevention in infants
Tan-Lim et al., 2021 — Pediatric Allergy and Immunology (2021) link
Other references
Hill et al., 2014 (ISAPP consensus) — Nature Reviews Gastroenterology & Hepatology (2014) link
Track Probiotics with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.